title: Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance.
abstract: Human cytomegalovirus UL97 kinase mutations that commonly confer ganciclovir resistance cluster in different parts of the gene than those conferring resistance to maribavir, an experimental UL97 kinase inhibitor. The drug resistance, growth, and autophosphorylation phenotypes of several unusual UL97 mutations in the kinase catalytic domain were characterized. Mutations V466G and P521L, described in clinical specimens from ganciclovir-treated subjects, conferred a UL97 kinase knockout phenotype with no autophosphorylation, a severe growth defect, and high-level ganciclovir, cyclopropavir, and maribavir resistance, similar to mutations at the catalytic lysine residue K355. Mutations F342S and V356G, observed after propagation under cyclopropavir in vitro, showed much less growth attenuation and moderate- to high-level resistance to all three drugs while maintaining UL97 autophosphorylation competence and normal cytopathic effect in cell culture, a novel phenotype. F342S is located in the ATP-binding P-loop and is homologous to a c-Abl kinase mutation conferring resistance to imatinib. UL97 mutants with relatively preserved growth fitness and multidrug resistance are of greater concern in antiviral therapy than the severely growth-impaired UL97 knockout mutants. Current diagnostic genotyping assays are unlikely to detect F342S and V356G, and the frequency of their appearance in clinical specimens remains undefined.
authors: Division of Infectious Diseases, Oregon Health and Science University, Portland, Oregon, USA. chous@ohsu.edu
authors: Sunwen
authors: S
authors: Chou
authors: Ronald J
authors: RJ
authors: Ercolani
authors: Gail
authors: G
authors: Marousek
authors: Terry L
authors: TL
authors: Bowlin
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology*; D001562:Benzimidazoles / Q000494:pharmacology; D020134:Catalytic Domain / Q000235:genetics*; D002460:Cell Line; D003521:Cyclopropanes / Q000494:pharmacology; D003587:Cytomegalovirus / Q000187:drug effects* / Q000201:enzymology* / Q000235:genetics / Q000254:growth & development; D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000821:virology; D018432:Drug Resistance, Multiple / Q000235:genetics; D024882:Drug Resistance, Viral / Q000235:genetics*; D015774:Ganciclovir / Q000494:pharmacology*; D005838:Genotype; D006147:Guanine / Q000031:analogs & derivatives / Q000494:pharmacology; D006801:Humans; D009154:Mutation; D010766:Phosphorylation; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D012263:Ribonucleosides / Q000494:pharmacology; D004004:Dichlororibofuranosylbenzimidazole / Q000031:analogs & derivatives
chemical_list: D000998:Antiviral Agents; D001562:Benzimidazoles; D003521:Cyclopropanes; D015774:Ganciclovir; D006147:Guanine; D017853:Phosphotransferases (Alcohol Group Acceptor); D012263:Ribonucleosides; C495219:cyclopropavir; C075365:ganciclovir kinase; C400401:maribavir; D004004:Dichlororibofuranosylbenzimidazole
references: Clin Cancer Res. 2006 Dec 15;12(24):7374-9
references: 17189410
references: Transplantation. 2010 Dec 27;90(12):1409-13
references: 21030903
references: J Gen Virol. 2001 Jun;82(Pt 6):1439-1450
references: 11369889
references: Antimicrob Agents Chemother. 2007 Nov;51(11):4160-2
references: 17709468
references: J Clin Virol. 2010 Apr;47(4):321-4
references: 20138805
references: J Clin Virol. 2010 Dec;49(4):296-8
references: 20843736
references: J Infect Dis. 2007 Jul 1;196(1):91-4
references: 17538888
references: Rev Med Virol. 2008 Jul-Aug;18(4):233-46
references: 18383425
references: Antimicrob Agents Chemother. 2005 Jul;49(7):2710-5
references: 15980340
references: Antimicrob Agents Chemother. 2012 Jan;56(1):197-201
references: 21968367
references: J Clin Virol. 2012 Mar;53(3):208-13
references: 22237003
references: Antimicrob Agents Chemother. 2011 Jan;55(1):382-4
references: 21041510
references: Science. 1988 Jul 1;241(4861):42-52
references: 3291115
references: Antimicrob Agents Chemother. 2005 Mar;49(3):1039-45
references: 15728900
references: Antivir Ther. 2009;14(5):697-704
references: 19704173
references: J Virol. 1999 Oct;73(10):8898-901
references: 10482650
references: Antimicrob Agents Chemother. 2006 Jul;50(7):2557-9
references: 16801445
references: Herpesviridae. 2010 Dec 07;1(1):4
references: 21429239
references: Transplantation. 2010 Apr 15;89(7):779-95
references: 20224515
references: Antimicrob Agents Chemother. 2010 Jun;54(6):2371-8
references: 20385869
references: J Gen Virol. 1998 Sep;79 ( Pt 9):2105-12
references: 9747718
references: J Antimicrob Chemother. 2010 Dec;65(12):2628-40
references: 20961907
references: Am J Transplant. 2012 Nov;12(11):3021-30
references: 22947426
references: Leuk Lymphoma. 2011 Feb;52 Suppl 1:12-22
references: 21299456
references: Lancet Infect Dis. 2011 Apr;11(4):284-92
references: 21414843
references: Antimicrob Agents Chemother. 2004 Dec;48(12):4745-53
references: 15561852
references: Clin Microbiol Rev. 2010 Oct;23(4):689-712
references: 20930070
references: J Virol. 2005 Dec;79(24):15494-502
references: 16306620
references: Antimicrob Agents Chemother. 2011 Oct;55(10):4682-91
references: 21788463
references: J Gen Virol. 2010 Oct;91(Pt 10):2531-41
references: 20592110
references: Blood. 2000 Nov 1;96(9):3286-9
references: 11050017
references: Rev Med Virol. 2009 Jul;19(4):215-29
references: 19434630
references: Antiviral Res. 2012 Aug;95(2):88-92
references: 22664236